Roivant Sciences stock is trading -22.32% below its average target price of $16.13 after dropping -5.0% during today's afternoon session. Analysts are giving the mid-cap Pharmaceutical company an average rating of buy and target prices ranging from $12.0 to $23.0 per share.
The stock has an average amount of shares sold short at 4.6%, and a short ratio of 4.03. Since 34.48% of the company's shares are owned by insiders, we can infer that there is a degree of alignment between management and shareholder interests. Finally, we also note that an average number of institutional investors are invested in the stock, with 58.5% of Roivant Sciences's shares being owned by this investor type.
Institutions Invested in Roivant Sciences
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2023-06-30 | QVT Financial LP | 16% | 122,541,536 | $1,535,445,413 |
| 2023-06-30 | SB Investment Advisers (UK) LTD | 11% | 83,031,667 | $1,040,386,765 |
| 2023-06-30 | Viking Global Investors, L.P. | 10% | 75,238,700 | $942,740,890 |
| 2023-06-30 | FMR, LLC | 5% | 35,997,134 | $451,044,079 |
| 2023-06-30 | Wellington Management Group, LLP | 2% | 15,196,555 | $190,412,830 |
| 2023-06-30 | Morgan Stanley | 2% | 12,986,716 | $162,723,548 |
| 2023-06-30 | Patient Square Capital LP | 2% | 12,639,920 | $158,378,194 |
| 2023-06-30 | Blackrock Inc. | 2% | 12,372,873 | $155,032,095 |
| 2023-06-30 | Adage Capital Partners GP L.L.C. | 1% | 11,090,300 | $138,961,456 |
| 2023-06-30 | State Street Corporation | 1% | 9,533,896 | $119,459,714 |
Besides an analyst consensus of strong upside potential, other market factors point to there being positive market sentiment on Roivant Sciences.
